ArticleOncogene2002
The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1.
Article in Oncogene, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 91 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed, 211 citations in OpenAlex.
- Epigenetic Landscape and Therapeutic Implication of Gene Isoforms of Doublecortin-Like Kinase 1 for Cancer Stem Cells.International journal of molecular sciences · 2023Review
- In silico analysis predicting effects of deleterious SNPs of human RASSF5 gene on its structure and functions.Scientific reports · 2020Article
- NORE1A directs apoptotic switch of TNF signaling through reciprocal modulation of ITCH-mediated destruction of TNFRI and BAX.Oncogene · 2020Article
- Signaling pathways and clinical application of RASSF1A and SHOX2 in lung cancer.Journal of cancer research and clinical oncology · 2020Review
- RASSF1A, puppeteer of cellular homeostasis, fights tumorigenesis, and metastasis-an updated review.Cell death & disease · 2019Review
- The Role and Function of Ras-association domain family in Cancer: A Review.Genes & diseases · 2019Review
- The tumor suppressor RASSF1A modulates inflammation and injury in the reperfused murine myocardium.The Journal of biological chemistry · 2019Article
- Cytogenetic characterization of the malignant primitive neuroectodermal SK-PN-DW tumor cell line.BMC cancer · 2019Article
- New type of interaction between the SARAH domain of the tumour suppressor RASSF1A and its mitotic kinase Aurora A.Scientific reports · 2019Article
- MRAS: A Close but Understudied Member of the RAS Family.Cold Spring Harbor perspectives in medicine · 2018Review
- Tumor suppressor C-RASSF proteins.Cellular and molecular life sciences : CMLS · 2018Review
- Impact of Natural Compounds on DNA Methylation Levels of the Tumor Suppressor Gene RASSF1A in Cancer.International journal of molecular sciences · 2017Review
- The role of the NORE1A tumor suppressor in Oncogene-Induced Senescence.Cancer letters · 2017Review
- RASSF1A methylation, YAP1 activation and metastasis: a new role for an old foe in lung cancer.Journal of thoracic disease · 2017Article
- Mutant allele specific imbalance in oncogenes with copy number alterations: Occurrence, mechanisms, and potential clinical implications.Cancer letters · 2017Review
- MST1/MST2 Protein Kinases: Regulation and Physiologic Roles.Biochemistry · 2016Review
- Ras signaling through RASSF proteins.Seminars in cell & developmental biology · 2016Review
- Review
- Enabling systematic interrogation of protein-protein interactions in live cells with a versatile ultra-high-throughput biosensor platform.Journal of molecular cell biology · 2016Article
- Voluntary wheel running reduces voluntary consumption of ethanol in mice: identification of candidate genes through striatal gene expression profiling.Genes, brain, and behavior · 2016Article
31 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Nore and RASSF1A are noncatalytic proteins that share 50% identity over their carboxyterminal 300 AA, a segment that encompasses a putative Ras-Rap association (RA) domain. RASSF1 is expressed as several splice variants, each of which contain an RA domain, however the 340 AA RASSF1A, but not the shorter RASSF1C variant, is a putative tumor suppressor. Nore binds to Ras and several Ras-like GTPases in a GTP dependent fashion however neither RASSF1 (A or C) or the C. elegans Nore/RASSF1 homolog, T24F1.3 exhibit any interaction with Ras or six other Ras-like GTPases in a yeast two-hybrid expression assay. A low recovery of RASSF1A (but not RASSF1C) in association with RasG12V is observed however on transient expression in COS cells. Nore and RASSF1A can each efficiently homodimerize and heterodimerize with each other through their nonhomologous aminoterminal segments. Recombinant RASSF1C exhibits a much weaker ability to homodimerize or heterodimerize; thus the binding of RASSF1C to Nore is very much less than the binding of RASSF1A to Nore. The association of RASSF1A with RasG12V in COS cells appears to reflect the heterodimerization of RASSF1A with Nore, inasmuch the recovery of RASSF1A with RasG12V is increased by concurrent expression of full length Nore, and abolished by expression of Nore deleted of its RA domain. The preferential ability of RASSF1A to heterodimerize with Nore and thereby associate with Ras-like GTPases may be relevant to its putative tumor suppressor function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.